FIRST REGULAR SESSION
SENATE BILL NO. 252
103RD GENERAL ASSEMBLY
INTRODUCED BY SENATOR MOON.
1086S.01I KRISTINA MARTIN, Secretary
AN ACT
To amend chapter 196, RSMo, by adding thereto three new sections relating to required disclosures
for certain products.
Be it enacted by the General Assembly of the State of Missouri, as follows:
Section A. Chapter 196, RSMo, is amended by add ing thereto 1
three new sections, to be known as sections 196.1400, 196.1405, 2
and 196.1410, to read as follows:3
196.1400. 1. For purposes of this section, the 1
following terms mean: 2
(1) "Cosmetic", the same meaning given to the term in 3
section 196.010, except that the term "cosmetic" shall 4
include soap; 5
(2) "Food", the same meaning given to the term in 6
section 196.010; 7
(3) "Gene therapy product", any product with any 8
capacity to alter, interfere with, or otherwise act in any 9
manner similar or equivalent to genes; 10
(4) "Product", any product that is: 11
(a) A food, cosmetic, or other substance intended to 12
be ingested, introduced into, or applied to the human body 13
or intended to induce physiological effects; and 14
(b) Made available for sale in this state to the 15
general public at retail. 16
2. Any product that has been created to act as, or 17
exposed to processes that could result in the product 18 SB 252 2
potentially acting as, a gene therapy or that could 19
otherwise possibly impact, alter, or introduce genetic 20
material or a genetic change into the user of the product, 21
individuals exposed to the product, or individuals exposed 22
to others who have used the product shall be conspicuously 23
labeled with the words "Potential Gen e Therapy Product" 24
unless the product is known to be a gene therapy product. 25
Reasonable steps shall be taken to ensure the potential 26
purchaser or user of the product is made aware of the 27
presence of this label. 28
3. If a product is known to be a g ene therapy product, 29
the product shall be conspicuously labeled with the words 30
"Gene Therapy Product". 31
4. The provisions of this section shall be liberally 32
construed in favor of disclosure of any potential gene 33
therapy product. 34
196.1405. 1. For purposes of this section, the 1
following terms mean: 2
(1) "Expose", transmit to another through skin -to-skin 3
contact, sexual activity, droplets or aerosols suspended in 4
the air, introduction into the blood supply or food supply, 5
or any other means; 6
(2) "Genetically modified", the alteration of genetic 7
material through modern biotechnology, directed evolution, 8
or any other mechanism in a way that does not occur 9
naturally or that does not occur at its natural rate. 10
2. Upon the written request of any resident of this 11
state, any entity that produces, sells, or distributes a 12
product in this state with the capacity to infect an 13
individual with a disease or to expose an individual to 14
genetically modified material, incl uding, but not limited 15
to, vaccines, gene therapies, drugs, and medical 16 SB 252 3
interventions, shall provide any and all information related 17
to the ways in which individuals who did not directly obtain 18
or use such product may be exposed to the product or a 19
component of the product. Any product manufacturer, 20
government agency, or organization of any type that has an 21
interest in the production, sale, or distribution of such 22
product shall be subject to the disclosure requirement of 23
this section and shall pro vide all relevant reports, 24
research, and knowledge upon request under this section. 25
3. Any entity described in subsection 2 of this 26
section shall provide the information requested under 27
subsection 2 of this section as soon as reasonably 28
practicable, but at least within twenty -one days, after 29
receipt of the written request to the resident who made the 30
request. 31
196.1410. Any entity that makes a product available in 1
this state that could infect, transmit to, or be absorbed in 2
any individual in any way that would act as a medical 3
intervention, vaccine, drug, or genetic modification shall 4
obtain fully informed consent from all individuals who could 5
be exposed to such product before exposure could occur. 6
Fully informed consen t requires, at a minimum, that an 7
individual is made aware of all benefits and risks, 8
including side effects of the product, any adverse events of 9
special interest, and any other reasonably possible impacts 10
of the product. 11